Universal Beteiligungs und Servicegesellschaft mbH Sells 55,708 Shares of Gilead Sciences, Inc. $GILD

Universal Beteiligungs und Servicegesellschaft mbH lessened its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 4.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,186,464 shares of the biopharmaceutical company’s stock after selling 55,708 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Gilead Sciences were worth $131,698,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the business. Rothschild Investment LLC boosted its holdings in shares of Gilead Sciences by 1.9% during the 2nd quarter. Rothschild Investment LLC now owns 4,539 shares of the biopharmaceutical company’s stock worth $503,000 after buying an additional 84 shares during the period. Hemington Wealth Management boosted its position in Gilead Sciences by 9.3% during the third quarter. Hemington Wealth Management now owns 998 shares of the biopharmaceutical company’s stock valued at $110,000 after acquiring an additional 85 shares during the last quarter. Ignite Planners LLC grew its holdings in Gilead Sciences by 1.1% in the third quarter. Ignite Planners LLC now owns 7,932 shares of the biopharmaceutical company’s stock worth $880,000 after purchasing an additional 86 shares during the period. Archer Investment Corp increased its stake in Gilead Sciences by 1.2% during the 2nd quarter. Archer Investment Corp now owns 7,277 shares of the biopharmaceutical company’s stock valued at $807,000 after purchasing an additional 87 shares in the last quarter. Finally, Binnacle Investments Inc lifted its stake in Gilead Sciences by 14.3% during the 2nd quarter. Binnacle Investments Inc now owns 702 shares of the biopharmaceutical company’s stock valued at $78,000 after acquiring an additional 88 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Price Performance

Shares of GILD stock opened at $124.14 on Wednesday. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31. The company’s 50-day simple moving average is $123.53 and its two-hundred day simple moving average is $118.29. Gilead Sciences, Inc. has a one year low of $91.84 and a one year high of $128.70. The company has a market capitalization of $154.02 billion, a P/E ratio of 19.25, a P/E/G ratio of 0.66 and a beta of 0.33.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The company had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.42 billion. During the same quarter in the previous year, the firm posted $2.02 earnings per share. Gilead Sciences’s revenue for the quarter was up 3.0% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th were given a dividend of $0.79 per share. The ex-dividend date of this dividend was Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.5%. Gilead Sciences’s dividend payout ratio (DPR) is currently 48.99%.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on GILD shares. Wall Street Zen upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 3rd. Weiss Ratings reissued a “buy (b)” rating on shares of Gilead Sciences in a research note on Wednesday, October 8th. UBS Group reissued a “buy” rating on shares of Gilead Sciences in a research report on Thursday, January 15th. Wolfe Research reissued an “outperform” rating and issued a $150.00 target price on shares of Gilead Sciences in a research report on Monday, December 15th. Finally, Royal Bank Of Canada upped their price target on Gilead Sciences from $100.00 to $103.00 and gave the stock a “sector perform” rating in a research report on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $133.28.

Insiders Place Their Bets

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $124.31, for a total transaction of $372,930.00. Following the completion of the sale, the insider directly owned 103,221 shares in the company, valued at approximately $12,831,402.51. The trade was a 2.82% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction that occurred on Friday, November 28th. The stock was sold at an average price of $125.08, for a total value of $625,400.00. Following the sale, the director directly owned 8,920 shares of the company’s stock, valued at $1,115,713.60. The trade was a 35.92% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 136,757 shares of company stock worth $16,951,612. Corporate insiders own 0.27% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.